Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 154.5% from a year ago
Cash & equivalents stood at $500.22M at the end of Q1 FY2026, up 154.5% from a year earlier and up 352.1% from the prior quarter. Over 3 fiscal years it compounded at +18.1% a year.
Context
- Cash & equivalents amounted to 66.9% of total assets at the end of Q1 FY2026, up 8.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +154.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 110.64M USD
- Year-over-year change
- -65.4%
- 3-year CAGR
- +18.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.64M | -65.4% |
| FY2024 | 2024-12-31 | 319.74M | +462.4% |
| FY2023 | 2023-12-31 | 56.86M | -15.4% |
| FY2022 | 2022-12-31 | 67.21M | — |
Cash & Equivalents vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 cash & equivalents of $500.22M is the 2nd highest of the 8 companies compared; the peer median is $96.72M.
- Its year-over-year change of +154.5% is the highest of 7, against a peer median of +21.7%.
- Cash & equivalents amounts to 66.9% of total assets for ZBIO, versus a peer median of 66.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $722.27M | +38.4% | +33.8% | 94.9% | |
| Mar 2026 | $500.22M | +154.5% | +18.1% | 66.9% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $248.47M | — | — | 85.5% |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
UPBUpstream Bio, Inc. | Mar 2026 | $96.72M | +35.6% | +81.3% | 30.4% |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Dec 2025 | $4.01M | +7.7% | -39.5% | 34.9% | |
| Peer median (excluding ZBIO) | $96.72M | +21.7% | +4.1% | 66.6% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.